Back to search

Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies

Data up to Jan 2025

Published1999
Citations205
References21

Total Citations Per Year

Abstract

References (21)

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

1992 • 483 citations

NMR and Molecular Modeling Investigation of the Mechanism of Activation of the Antitumor Drug Temozolomide and Its Interaction with DNA

1994 • 417 citations

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.

1987 • 386 citations

Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.

1995 • 290 citations

Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours

1993 • 276 citations

Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma

1997 • 221 citations

The charing cross hospital experience with temozolomide in patients with gliomas

1996 • 157 citations

Activity of temozolomide in the treatment of central nervous system tumor xenografts.

1995 • 145 citations

In vitro evaluation of temozolomide combined with X-irradiation

1997 • 144 citations

Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea.

1994 • 131 citations

3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity

1996 • 121 citations

Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.

1997 • 94 citations

In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas.

1987 • 75 citations

Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study

1996 • 74 citations

Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity

1990 • 65 citations

Effect of single and multiple administration of an O ? 6 -benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model

1997 • 59 citations

Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction

1995 • 55 citations

Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: Studies with blasts of leukaemic patients

1995 • 53 citations

High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma

1997 • 44 citations

Neck Dissection: Past, Present, Future

2005 • 42 citations

High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma

1997 • 13 citations

Cited By (0)

Loading...
Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for… (1999) – British Journal of Cancer | Metascience Observatory Explorer